


**AZENTA**  
LIFE SCIENCES

December 15, 2021

Dear Fellow Stockholders,

Fiscal 2021 was a momentous year for the company, marking several key milestones for our business. On top of continued record performance, we executed on strategic initiatives to transform our profile and enhance future growth prospects. As of December 1<sup>st</sup>, we officially changed our name and stock ticker to Azenta, Inc. (Nasdaq: AZTA) from Brooks Automation, Inc. (Nasdaq: BRKS). Earlier this year, we announced our intention to separate the Life Sciences and Semiconductor Solutions businesses, and in September, we announced the pending sale of the Semiconductor Solutions business to Thomas H. Lee Partners, which is expected to close in the first half of calendar 2022. Upon completion of the sale, we will become a standalone pure-play life sciences company. As Azenta, we believe we are uniquely positioned to support life sciences companies to bring impactful breakthroughs and therapies to market – faster.

From a macroeconomic lens, 2021 was another year marked by the COVID-19 pandemic and its many hardships, but also by the unwavering dedication and perseverance of many individuals and organizations that have continued to move our society forward. Our employees at Azenta continued to rise to the occasion to meet customer needs in a challenging environment. As a company, we continue to prioritize the safety of our employees, customers and suppliers through comprehensive safety protocols, which have served us well. We thank our employees for their hard work and efforts to drive the strong performance of the past year.



## 2021 Recap

In aggregate, revenue grew 33% with both Life Sciences and Semiconductor Solutions segments growing over 30%. Due to the divestiture announced on September 20, 2021, as of our fourth fiscal quarter, the results of the Semiconductor Solutions business are treated as discontinued operations.

Continuing operations of Azenta Life Sciences achieved revenue growth of 32%, non-GAAP EPS of \$0.48 and non-GAAP EBITDA margin expansion of 950 basis points. In November, we held an investor day and provided a 3-year target model to 2024, which outlined our plans for continued growth and margin expansion in the years ahead.

## Azenta Life Sciences

Fiscal 2021 was a milestone year for our Life Sciences business as we achieved over half a billion dollars in revenue with strong organic growth across all of our major business lines.

In January, we hired the Company's first Chief Commercial Officer to centralize and streamline our sales organization for long-term scalable growth. We have already begun to see early successes from the new structure and have a growing pipeline of opportunities that will benefit from our new, "One Azenta" approach.

Our Products business experienced rapid growth over the past year due to strength in both our consumables and instruments (C&I) and automated storage offerings. In C&I, we saw increased demand for our PCR plates and tubes in support of research and testing to combat the ongoing COVID-19 pandemic. The team expertly managed our supply chain and filled orders where others could not. We believe this ability to deliver for customers has accelerated the expansion of our customer base and opened the door to new relationships that will drive growth in the future. In automated stores, we have had several large wins over the past year, including our largest store in the company's history – an automated store with the capability to manage up to 100 million

samples. Our BioStore Cryo system is gaining traction with cell and gene therapy customers leading to multiple and repeat system orders as well as with customers managing master cell lines and other precious sample collections.

In our Sample Repository Solutions business we made significant strides, notably, two contract wins with large pharmaceutical companies, the opening of our Cleveland Clinic facility, and continued expansion into the management of manufactured product, including a large contract to supply a variety of vaccines to the United States military reservists. Our customers see the value in partnering with us – we believe our cold sample logistics expertise, rapid retrieval, and sample-level trackability are unrivaled in the business. We continue to invest in our biorepository infrastructure and expect to see the benefit of the fiscal 2021 contract wins drive growth in fiscal 2022 and beyond.

Our Genomics Services business provides critical insights to scientists and researchers around the globe. The demand for genomic analysis in the research community continues to grow, and the Azenta team is ready and uniquely positioned to support these needs. With our network of more than 400 advanced degree scientists across the globe, access to the latest sequencing technologies, and a keen focus on quality with speed, we aim to deliver the highest level of service for our customers. In the cell and gene therapy space, we support customers through their most challenging experiments, and we continue to expand our offerings and capabilities to support this fast-growing area of the market. We are gaining traction and recognition for our innovative capabilities such as our full suite of AAV-ITR offerings, and this is just the beginning.

### **Semiconductor Solutions**

The 2021 performance of the Semiconductor Solutions business was also notably robust with revenue growth of 34%. The semiconductor capital equipment market remains strong with high demand, and the team has done a remarkable job to mitigate supply constraints through close collaboration with our customers and suppliers.

Due to its long respected history, the semiconductor business will continue to carry the Brooks Automation name and brand. Our support for this business and the Brooks team remains strong. We are confident in the outlook, and we will continue to operate as we always have up until completion of the sale. The team is working diligently to ensure a smooth transition to new ownership, which is anticipated to occur in the first half of calendar year 2022.

### **Looking Forward**

The team at Azenta is energized and enthusiastic about the opportunities ahead. We have a unique life sciences portfolio with highly valuable sample solutions to accelerate discovery and delivery across all phases of development for a large and growing customer set. As we enter 2022, we continue to build on our strong foundation of market leadership and product and service excellence. We have positioned ourselves in the fastest growing areas of life sciences and continue to innovate and invest to stay ahead of market trends. In addition, with the anticipated closure of the sale of the Semiconductor Solutions business, we expect to have over \$2.5 billion of capital to deploy to scale and expand the capabilities of our global platform.

Our business is high growth and profitable with meaningful margin expansion opportunity. We have a strong balance sheet and a track record of responsible capital deployment, and most importantly, we have the right team in place to execute. We look forward to delivering on these commitments in 2022 and beyond.

On behalf of our Board of Directors and the entire global Azenta team, we thank our stockholders for their continued support and confidence, and we look forward to continued success in 2022.

Sincerely,



Steve Schwartz  
President and Chief Executive Officer